| Characteristics . | . |
|---|---|
| Male sex - n (%) | 14 (93) |
| Median age (range) | 43 (26–58) |
| Race or ethnicity | |
| White non-Hispanic | 5 |
| Black non-Hispanic | 6 |
| Hispanic, regardless of race | 3 |
| Multiple, non-Hispanic | 1 |
| HIV RNA <50 copies/ml (day 0) – n (%) | 15 (100) |
| CD4 T cell count – cells/mm3 | |
| Median (range) | 688 (391–1,418) |
| Nadir CD4 T cell count – cells/mm3 | |
| Median (range) | 350 (250-500) |
| Years since starting ART | |
| Median (range) | 11 (1-21) |
| Years on uninterrupted ART | |
| Median (range) | 7 (2-16) |
| ART regimen – n (%) | |
| Integrase inhibitor based | 5 (33) |
| Protease inhibitor based | 2 (13) |
| NNRTI based | 8 (53) |
| 3BNC117 IC50 <2.0 µg/ml – n (%) | 10 (67) |
| Characteristics . | . |
|---|---|
| Male sex - n (%) | 14 (93) |
| Median age (range) | 43 (26–58) |
| Race or ethnicity | |
| White non-Hispanic | 5 |
| Black non-Hispanic | 6 |
| Hispanic, regardless of race | 3 |
| Multiple, non-Hispanic | 1 |
| HIV RNA <50 copies/ml (day 0) – n (%) | 15 (100) |
| CD4 T cell count – cells/mm3 | |
| Median (range) | 688 (391–1,418) |
| Nadir CD4 T cell count – cells/mm3 | |
| Median (range) | 350 (250-500) |
| Years since starting ART | |
| Median (range) | 11 (1-21) |
| Years on uninterrupted ART | |
| Median (range) | 7 (2-16) |
| ART regimen – n (%) | |
| Integrase inhibitor based | 5 (33) |
| Protease inhibitor based | 2 (13) |
| NNRTI based | 8 (53) |
| 3BNC117 IC50 <2.0 µg/ml – n (%) | 10 (67) |